Skip to search formSkip to main contentSkip to account menu

Azacitidine Injection [Vidaza]

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

Azacitidine 100 MG Injection [Vidaza]
InjectionVidaza

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine…
Azacitidine (Vidaza®) is the standard treatment for patients with higher‐risk myelodysplastic syndromes (MDS) not eligible for… 
2012
2012
Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses.
Azacitidine (5-azacytidine, VIDAZA) is a disease-modifying agent that improves survival, reduces transfusion dependence, and… 
2011
2011
Cautions Regarding the Fitting and Interpretation of Survival Curves
The UK National Institute for Health and Clinical Excellence (NICE) has used its Single Technology Appraisal (STA) programme to… 
2011
2011
Combining Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) as First Salvage Treatment in Patients (PTS) With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing…
2010
2010
Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) In Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell…
Abstract 1294 Background: Patients with AML or MDS who relapse after allogeneic HSCT have a poor prognosis and therapeutic… 
2009
2009
DNA Methylation Changes Following 5-Azacitidine Treatment in Patients with Myelodysplastic Syndrome.
Abstract 2791 Poster Board II-767 Gene silencing by promoter methylation is as potent as functional inactivating of tumor… 
2009
2009
Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes
So far, treatment options for patients with higher risk myelodysplastic syndromes (MDS) have been quite limited. For azacitidine… 
2007
2007
Preliminary Results from a Phase I Study of Revlimid® (Lenalidomide) in Combination with Vidaza® (Azacitidine) in Patients with Advanced Myelodysplastic Syndromes (MDS).
Background: Early MDS becomes more advanced as immature myeloid cells proliferate, angiogenesis increases, genetic lesions… 
2006
2006
Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.
Efficacy and safety of azacitidine (Vidaza®), at the FDA-approved dosing schedule of 75 mg/m2/day x 7 days every 28 days, was… 
Review
2004
Review
2004
Treatment options for myelodysplastic syndromes.
Current approaches and novel therapeutics on the horizon for myelodysplastic syndromes are discussed. 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)